chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Five days after my second dose of vaccine, I developed itching; This is a spontaneous report from a contactable consumer. This consumer (patient) reported for self that,  A 72-years-old patient of an unspecified gender received bnt162b2 (BNT162B2, Formulation: Solution for injection, Batch/Lot Number: ER8727) (at the age of 72 years old), dose 2 via an unspecified route of administration, administered in arm left on 13Apr2021 as dose 2, single for covid-19 immunisation. Historical vaccine, the patient took first dose bnt162b2 (BNT162B2, Formulation: Solution for injection, Batch/Lot Number: EN6198), dose 1 via an unspecified route of administration, administered in arm left on 22Mar2021 as dose 1, single for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. It was reported that, after patient's second dose of vaccine patient developed itching and it has already been seven days when they got itchy. Patient was taking Benadryl for the event. The outcome for the event was not recovered.  No follow-up attempts are needed. No further information is expected.
approx 5 1/2 hrs p/receiving vax started prolonged crying, had extremely red leg & swelling, vomited; approx 530PM had sx & was taken to hosp; t105 R; leg still red, sore & swollen;
5Oct90 /p the 2nd dose of Engerix B, pt experienced sweating;malaise;chills;weakness;headache;severe nausea & vomiting;abd cramps & muscular neuralgia, pt went to ER, was not admitted.
Admitted for sepsis 2/2 COVID infection. Vaccinated x3. Treated with O2, steroids, cefepime and azithro, remdesivir. Improved, weaned to RA and was discharged home.
Localized swelling about 1.5" x 1.5" to injection site.
Soreness at site X 3 days persistently and then continues off and on when body aches are present,  prolonged severe fatigue  and body aches persistently (still present as of today?s date), severe and persistent headache, blurred vision
On 02/23/2001 the patient experienced a mild case of chicken pox with about 15 pox. He was seen by a physician who diagnosed chicken pox on 02/23/2001. It was noted that one child in the patient's day care had chicken pox just prior to this event. Subsequently the patient recovered. Unspecified medical attention was sought.
This non-serious spontaneous case, was initially received from other health professional (nurse) on 03-Oct-2017, concerning a 39-year-old adult female patient. The patient's historical vaccine included unspecified influenza vaccine without any reaction. The patient's current condition included occasional reaction to egg, but did not react with an egg based vaccine in the past. The patient's concomitant medications were not reported. On 29-Sep-2017, the patient was administered with FLUCELVAX QIV (dose: 0.5 ml, batch number: 195126, expiry date: 30-Apr-2018, route of administration and anatomical location: not reported). It was reported that, within 24 hours of vaccination, the patient had symptoms of localized redness, swelling and heat at the site of minor intensity, which lasted for 3 days. No treatment was given for the events. At the time of this report, the outcome of the events was recovered. The reporter assessed the report as non-serious. Non-significant case correction received 03-Oct-2017: Batch number (195126) was added on the screen and updated expiry date. The narrative was amended accordingly.
pt recv vax & felt sharp sting on opposite (under) side of lt arm just above the elbow;itched profusely;original stinging sensation was followed by scattered pink prick sensation over a period of an hr or more;turn red & feverish & itched;
I called my physician when I got the positive results of my COVID-19 test, I had no symptoms. My doctor told me to isolate in my home away from everyone for 5 days and I would be able to leave my house on day 6 with a mask. My doctor advised for me to take over the counter medications if I had any symptoms. I tested again for COVID-19 on 6/30/22 and my test was still positive.
Patient started having face numbness after about 3 minutes of administration of vaccines and chest tightness after 5 minutes. I administered an EpiPen 0.3mg in her left thigh which helped with her chest tightness after 3 minutes. My staff called 911 and the EMT's arrived and took her vitals. Her vitals were normal but they ended up taking her to the ER.
This is a spontaneous report received from a contactable consumer or other non-HCP, program ID: (005570). A male patient received the 2nd dose of BNT162B2 (Pfizer-BioNTech COVID-19 vaccine, batch/lot# unknown), on Jun 7, 2021, single dose, for COVID-19 immunization. Medical history and concomitant medications not reported. Vaccination history included the 1st dose of the COVID-19 vaccine for immunization. Within a few days, his whole urinary tract from the bladder down has been inflamed. He had 4 operations and still in pain. They are suggesting he have his bladder removed. Therapeutic measures were taken as a result of urinary tract inflammation. The outcome of the events: unknown. Information on the batch/lot number for BNT162B2 requested and will be submitted if/when received.
This case was reported by a healthcare professional and described the occurrence of vomiting in a 63-year-old male subject who was vaccinated with FLULAVAL (GlaxoSmithKline). Concurrent medications included COUMADIN, TRILIPIX, CRESTOR, EXFORGE, ULORIC, COLCRIP? and LYRICA. On 11 October 2011 at 11:30 the subject received a dose of FLULAVAL in the right arm. On 11 October 2011, less than one day after vaccination with FLULAVAL, the subject experienced vomiting, chills, fever, body pain and lethargy. The healthcare professional considered the events were clinically significant (or requiring intervention). At the time of reporting the events were resolved. The healthcare professional considered the events were probably related to vaccination with FLULAVAL.
Prevnar 20 was given to a 4-month-old instead of a Prevnar 13 for his second dose. Once error was caught, I contacted the CDC and manufacturing company for recommendations, reactions, and dosing. Mother of the patient was then contacted and informed of all information that was given, stated that the only reactions patient had were similar to any reaction of vaccines as well as a bit fussier, diarrhea and waking up more often at night. Mother then 1 week later reported that patient has had a rash around the mouth and chin and feeding issues.
shingles; This spontaneous report has been received from a lawyer regarding a case in litigation, concerning a female patient of unknown age. The medical history, concurrent conditions and concomitant medications were not provided. In 2014, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (strength, lot #, expiration date, dosage, anatomical location and route of administration were not reported) by a pharmacist at a pharmacy, for the long-term prevention of shingles and zoster-related conditions. Subsequent to vaccination, the patient was treated by a healthcare provider at a hospital for shingles. As a direct and proximate result of zoster vaccine live (ZOSTAVAX) use, the patient had and will continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for those injuries; significant medical and related expenses as a result of those injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future. The outcome for herpes zoster was not recovered.
After first shot (3/6/2021), had dystonic reaction 4 days after.  Went to ER and it was believed to have been Benadryl allergy.  I just took the 2nd dose and within 20 minutes, dystonic reaction started.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 63-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 19Apr2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 63 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Kidney disease" (unspecified if ongoing), notes: Kidney disease. Concomitant medication(s) included: WELLBUTRIN; SERTRALINE; DEXTROAMPHETAMINE [DEXAMFETAMINE]. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2022, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19. Patient has no known allergies.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
This medical assistant (MA) reports that this 42 year old female consumer received 0.5mL of Pneumovax (pneumococcal vaccine) IM in her right deltoid at a local health center on 27Jan2011. The patient's relevant medical history includes no history of a previous allergy or reaction to Pneumovax. She had not received this vaccine before. The patient's relevant concomitant medications include: The patient was taking unspecified antihistamine medications per the patient's report. On 27Jan2011, this MA reports that per a physician's request she ran the LCR immunization rules and verified that the patient was recommended to have the Pneumovax vaccine. The MA asked the patient routine adult screening questions for immunizations. Patient denied any contraindications, and possible side effects of the Pneumovax vaccine were discussed. On 27Jan2011, a dose of the Pneumovax vaccine was administered to the patient. The patient and MA walked to the MA's office to set a future appointment and patient stated she felt "something was wrong, her tongue felt like it was swelling. Then her face began to turn red and she became very sweaty. The MA told her to breathe slow and called for a nurse on the voicera. An RN arrived and MA went to notify the physician. Pulse oximetry was checked and it was normal. The patient began to return to her normal color and stated she was feeling better. The physician ordered two of Benadryl 25mg to be given now. MA took the prescription to the pharmacy while the RN stood with the patient. The patient took Benadryl and we had her return to room where she wanted to lay down and we told her we would keep an eye on her for at least 30 minutes. After 30 minutes with the RN observing the patient, the patient stated she felt better and went to the bathroom. When she returned she was cleared to leave after her vitals signs were checked and they were stable. Allergy to Pneumovax was added to the patient's medical record for future use.
Fever, chills, headache    Extreme tiredness    Red swollen injection site. Hot to the touch injection site.  Dizziness.  Went to urgent care got a steroid shot.  It helped with swelling and redness of injection site.  Tiredness lasted for 1 week.
allergic reaction; broke into hives around the body; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSENSITIVITY (allergic reaction) and URTICARIA (broke into hives around the body) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J20-2A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In January 2021, the patient experienced HYPERSENSITIVITY (allergic reaction) and URTICARIA (broke into hives around the body). At the time of the report, HYPERSENSITIVITY (allergic reaction) and URTICARIA (broke into hives around the body) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported.  No information on treatment medication at the time of first dose was reported.   This case was linked to MOD-2021-032898 (Patient Link).
Pt vax /w DTP/OPV developed T 103, did not sleep @ night. He kept on crying. Seen again on 18OCT for Rt Otitis media & 21OCT /w skin rash.
Significant drowsiness, muscle/ body fatigue, muscle/ hand tremors in left arm/ hand. Tremors lasted for several days and the arm/ hand was significantly weaker, could not make a fist easily. This went away after a few days.
This spontaneous report as received from a medical assistant refers to a 15 year old female patient. The patient was not pregnant. No information regarding the patient's medical history or concurrent conditions was provided. On an unknown date, the patient was vaccinated with a dose of either GARDASIL or GARDASIL 9 injection (strength, dose, route of administration, lot# and expiry date were not reported). The reporter could not specify which dose it was in the vaccination series or whether the product used was GARDASIL or GARDASIL 9. There were no concomitant therapies reported. On an unknown date, the patient experienced vomiting. The patient sought medical attention (office visit on an unspecified date) and received treatment with soda. There was no product quality complaint (PQC) involved. The outcome of the event was reported as recovered on an unspecified date. The relatedness between GARDASIL or GARDASIL 9 and the event was not provided. Additional information has been requested.
Fairly significant area of redness and swelling to injection site. Redness, swelling and itching at injection site and surrounding area.
fatigue 21DEC92 3PM @ 5PM nausea, vomiting began 10PM x 1; fever 101, sweating still w/nausea today;
Initially, lump and tenderness at injection site, which dissipated within 3 days. Chills, sweats, muscle pain, lightheadedness, headache began 3-4 days following vaccine and lasted approximately 3 full days
This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu like symptoms), PYREXIA (Fever), COUGH (Cough), OROPHARYNGEAL PAIN (Sore throat) and RHINORRHOEA (Runny nose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported.On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms), PYREXIA (Fever), COUGH (Cough), OROPHARYNGEAL PAIN (Sore throat) and RHINORRHOEA (Runny nose). At the time of the report, INFLUENZA LIKE ILLNESS (Flu like symptoms), PYREXIA (Fever), COUGH (Cough), OROPHARYNGEAL PAIN (Sore throat) and RHINORRHOEA (Runny nose) outcome was unknown.    The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. Concomitant medication was not provided Treatment information was not reported
Pt recvd 3 doses of Engerix-B 27MAR91; 2MAY91 & 25SEP91 & it was determined that pt was a non-responder;
I got Covid after receiving my booster (5th shot).  My symptoms were a slight cough, headache, stuffy nose, and fatigue.
It was reported that a female patient received a rabies vaccination on 4-Aug-2000. Reportedly that same day, the patient complained of swelling the size of an egg and itching. This was the third pre-exposure dose and was administered in the forearms.  From additional correspondence received 28-Sep-2000, additional patient, vaccine and physician information was provided. No further information is expected, this case is closed.
Headache - nausea all Hives 25 mg BENADRYL oral given w/good recovery
This spontaneous report was received from a healthcare worker and refers to a 12 month old patient of unknown gender. The patient's concurrent conditions, past medical history were not reported. On 11-DEC-2015, the patient was vaccinated with an improperly stored M-M-R II (lot # K021151, expiry date 02-NOV-2016, dose, strength, vaccination site, dose number unspecified). Concomitant medications were not provided. No adverse effects were reported. Product quality complaint (PQC) was not reported. On 26-JAN-2016, a phone call was placed to the physician. The physician was unavailable at the time of call. The phone call was transferred to the Certified Medical Assistant (CMA). The C.M.A was unable to place specific lot numbers for each of the reported vaccines that experienced a temperature excursion; M-M-R II, ROTATEQ and VAQTA, with the information already supplied for patient identifiers, date of birth and date of vaccination, at this time. The C.M.A will need to review the records. This is one of the several reports received from the same reporter. Additional information has been requested.
Shingrix possible late second dose/ received Shingrix first dose on 2021; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 59-year-old female patient who received Herpes zoster (Shingrix) (batch number 47AY2, expiry date 26-SEP-2025) for prophylaxis.   Previously administered products included Shingrix (In 2021, received first dose).   On 13-NOV-2023, the patient received the 2nd dose of Shingrix. On 13-NOV-2023, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Shingrix possible late second dose/ received Shingrix first dose on 2021). The outcome of the drug dose administration interval too long was unknown.   Additional Information: GSK receipt date: 13-NOV-2023 A pharmacist had an immunocompetent patient whose doctor stated that patient received Shingrix first dose in 2021, however pharmacist did not have any records on that. The doctor recommended to start over the series. The pharmacist had just given a Shingrix dose on the day of reporting. The reporter consented to follow up. The patient received the second dose of Shingrix later than recommended schedule, which led to lengthening of vaccine schedule.
1430 Client called to say she got a HA about 15 min after leaving our dept. She says she took MOTRIN 600 mg at 11:30 with no relief. History 2 migraines in lifetime - feels like same thing at 15:40 says getting better.
Red blister like pustules on arm that the injection was given in. Appeared from wrist to shoulder. Given clobetasol from MD and symptoms resolved some minor scarring remained.
no previous history of covid and was fully vaccinated being very sick due to the delta variant; no previous history of covid and was fully vaccinated being very sick due to the delta variant; This is a spontaneous report from a contactable consumer from a Pfizer- Sponsored Program, reporting same event under the same suspect product for three patients. This is one of three reports. A patient of unspecified age and gender received BNT162B2 (Batch/Lot number was not reported), dose 1 and dose 2, both via an unspecified route of administration on an unspecified date as single dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. On an unspecified date, the patient with no previous history of covid and was fully vaccinated being very sick due to the delta variant, and was in the hospital. The outcome of event was unknown.  The lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202101042703 Same reporter/event/drug, different patient;US-PFIZER INC-202101095250 Same reporter/event/drug, different patient
Patient developed rash around throat and top of chest 30 minutes after receiving vaccine. She also developed a cough and stated she was itchy. She was given 50mg of benadryl and continued to be monitored at pharmacy for 15 more minutes. After 15 minutes she received benadryl she reported she felt fine and stated the itching had gone away. She also stopped coughing and the rash started to clear. A neighbor came to pick her up and we recommended she get checked by the ER as a precaution.
swelling; a little rash on right arm; rash on left arm; headache; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING (swelling), RASH (a little rash on right arm), RASH (rash on left arm) and HEADACHE (headache) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Allergy to vaccine.    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced SWELLING (swelling), RASH (a little rash on right arm), RASH (rash on left arm) and HEADACHE (headache). At the time of the report, SWELLING (swelling), RASH (a little rash on right arm), RASH (rash on left arm) and HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.No treatment information was provided.
Patient presented to hospital from her PCP office for worsening bilateral buttock pain with noted erythema and tenderness with some blistering with the left buttock area more tender and indurated than the right side. Patient noted that no trauma was involved to the areas. She noted tat she had the initial tenderness to both buttocks since the previous day but since that time they have progressively gotten worse and she feels as though the left buttock has been developing a blistering appearance to the rash. She denied any other recent symptoms of fever, chills, dizziness, syncope, blood in urine/stool/sputum, dysuria, abdominal pain/nausea/vomiting/diarrhea. She also noted that she had been having increasing amounts of leg swelling but is uncertain as to how long it had been worsening.
Fever, headaches, body aches, chills, sweats, exhaustion, coughing
parents noted bright red, raised, warm area on rt upper arm 27-29hr p/vax;area look better on office visit of AM 14NOV97;
pt recv vax & devel an inj site rxn characterized by redness & swelling;pt also exp knots & elevated temp around the inj site;this is one of 6 pt from this site to report adverse rxn;
Developed invasive pneumococcal disease (pneumonia with empyema and hemolytic uremic syndrome) beginning 10/27/2003.  Still hospitalized in pediatric intensive care unit at the time this form completed. Per review of ER record and history and physical from admitting hospital, states respiratory distress, fever, cough, vomit, tachypnea, diaphoresis, and pleural effision. The 60 day follow up received on 1/6/04 states pt moved away from this area. No longer am able to see her for follow up.
Patient fully vaccinated and hospitalized with COVID 7/25/22.  COVID-19  02/08/2021  1 of 3  Spikevax-MOD 100mcg  Full     COVID-19  03/08/2021  2 of 3  Spikevax-MOD 100mcg  Full     COVID-19  01/03/2022  3 of 3  Spikevax-MOD 100mcg  Full